In sud­den re­vamp, Cel­gene CEO Alles bids his COO good­bye and looks to re­gain con­fi­dence with man­age­ment shuf­fle

Stag­gered by a se­ries of late-stage set­backs capped by the FDA’s re­fusal to ac­cept its ap­pli­ca­tion on their lead­ing late-stage drug and look­ing vul­ner­a­ble on its num­bers, Cel­gene CEO and chair­man Mark Alles is re­vamp­ing the lead­er­ship struc­ture at the wob­bly biotech.

Num­ber one on the to-do list: Scott Smith is out as pres­i­dent and COO, with im­me­di­ate ef­fect. He’s not re­tir­ing or off in search of new op­por­tu­ni­ties. He’s just out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.